Asukamycin is an unusual trienoic acid amide metabolite produced by Streptomyces nodosus, reported by Omura and colleagues at the Kitasato Institute, Japan, in 1976. Asukamycin belongs to the manumycin class that comprises two trienoic acid amides pivoted on a central cyclohexenone ring to give the molecule an unprecedented angular geometry. Asukamycin is active against Gram positive bacteria, tumor cell lines and protozoans, notably coccidia. Asukamycin’s cell toxicity is accompanied by activation of Caspases 3 and 8.
ChEBI: A polyketide that is a member of the manumycin family of antibiotics and exhibits strong antibacterial, antifungal, and antineoplastic activities. Isolated from from the actinomycete bacterium Streptomyces nodosus subsp. asukaensis
Asukamycin (0-450 mg/kg; i.p.; mice) has low toxicity in vivo. Asukamycin has acute toxicity with an LD50 value of 48.5 mg/kg by intraperitoneal injection[2].
| Animal Model: | Mice[2] |
| Dosage: | 0-450 mg/kg |
| Administration: | Intraperitoneal injection |
| Result: | Had no effect on mice when administered by 450 mg/kg and the acute toxicity (LD50) was 48.5 mg/kg by intraperitoneal injection. |
